



YOUR VISION IS OUR VISION™

Oxurion Announces Upcoming Preclinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 11, 2022

Leuven, BELGIUM, Boston, MA, US – 11 April 2022 – 7.00 AM CET – [Oxurion NV](#) (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, will be presenting preclinical data from a study evaluating THR-687 for treatment of diabetic macular edema (DME) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held in Denver, Colorado on May 1-4th and virtually on May 11-12th. The presentation will review preclinical data supporting THR-687 providing protection against retinal vascular permeability, inflammation and reactive gliosis in the diabetic rat.

THR-687 is a highly selective pan-RGD integrin antagonist that is initially being developed as a potential first line therapy for DME patients and may have the potential to deliver improved treatment outcomes for patients with wet macular degeneration (wet AMD) and macular edema following retinal vein occlusion (ME-RVO). Oxurion is currently evaluating THR-687 in a two-part Phase 2 clinical trial ("INTEGRAL") in patients with DME. Part A dose optimization data from the INTEGRAL trial is anticipated in the first half of 2022. If successful, the efficacy and safety of THR-687 versus aflibercept (the current standard of care) will be evaluated in Part B of the INTEGRAL Phase 2 clinical trial in both treatment-naïve and treatment-experienced patients with DME. The pre-clinical data supports the view that THR-687 provides protection in the diabetic rat against retinal vascular permeability, inflammation and reactive gliosis.

Details of the presentation:

TITLE: THR-687, a potent pan-RGD integrin antagonist, protects against retinal vascular permeability, inflammation and reactive gliosis in the diabetic rat

PRESENTER: Tine Van Bergen, Senior Scientist, Oxurion NV

PRESENTATION DATE AND TIME: Tuesday, May 3, 2022, 12:47 p.m. ET